London-based Anemo Labs raises £455k for electronic nose technology

Digitizing the sense of smell through AI-powered sensors is the core mission of Anemo Labs Limited, which has just raised an estimated £455k. Based in London, the biotechnology research company is developing a handheld electronic nose designed to detect volatile compounds in real time.

Incorporated in January 2025, Anemo Labs focuses on creating non-invasive solutions for screening and monitoring biomarkers in bodily fluids. The technology utilizes a combination of hardware sensors and artificial intelligence models to identify specific chemical signatures. While the primary application is early disease diagnostics within the healthcare sector, the company also targets the food and environmental industries for quality and safety monitoring.

The current funding round reached an estimated size of £455k, with formal documentation filed in April following an allotment of shares in March. This is the first major capital injection for the startup since its inception.

Anemo Labs currently maintains a lean operation with three employees listed on its professional profile. As a development-stage company less than eighteen months old, detailed financial metrics regarding revenue, profit, or loss have not been disclosed in public filings. The capital is expected to support the continued development of their sensor hardware and the refinement of the AI models that power their volatile compound detection platform.

The company's website indicates that their goal is to provide a digital interface for olfactory data, moving beyond traditional laboratory-based chemical analysis toward portable, real-time diagnostic tools. This funding allows the London-based team to progress their research and development efforts in the biotechnology sector.